Research and experimental development on natural sciences and engineering
EFFIX PHARMA AS
Revenue 2025
NOK 0
Operating profit
NOK −22,000
Equity
NOK −4.1m
Incorporated
2008
Share capital
NOK 100,000
Key figures · 2025
Current ratio
0.04
Equity ratio
-16390.8%
Key figures over time · 2025
| Key figures | 2025 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Return on assets (%%) | -88.8% | |
| Likviditet | ||
| Current ratio | 0.04 | |
| Working capital | −667k | |
| Soliditet | ||
| Equity ratio (%%) | -16390.8% | |
| Debt-to-equity ratio | -1.01 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.